We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns

By LabMedica International staff writers
Posted on 11 Aug 2020
Print article
Structure of the RGS1 protein (Photo courtesy of Wikimedia Commons)
Structure of the RGS1 protein (Photo courtesy of Wikimedia Commons)
A genomics-based blood test can predict likelihood that a baby suffering hypoxia at birth will suffer serious nervous disorders such as cerebral palsy or epilepsy at a later stage of development.

Hypoxic ischemic encephalopathy has many causes and is essentially the reduction in the supply of blood or oxygen to a baby's brain before, during, or even after birth. It is a major cause of death and disability, occurring in approximately two to three per 1000 births and causing around 20% of all cases of cerebral palsy.

Brain hypothermia, induced by cooling a baby to around 33 degrees Celsius for three days after birth, is a treatment for hypoxic ischemic encephalopathy. It has recently been proven to be the only medical intervention which reduces brain damage, and improves an infant's chance of survival and reduced disability.

Since a rapid and early diagnostic test to identify the encephalopathic babies at risk of adverse outcome has been lacking, investigators at Imperial College London (United Kingdom) have developed one.

The investigators theorized that a whole blood transcriptomic signature measured soon after birth would predict adverse neurodevelopmental outcome eighteen months after neonatal encephalopathy. To test this hypothesis, they performed next generation sequencing (NGS) on whole blood ribonucleic acid obtained within six hours of birth from the first 47 encephalopathic babies recruited to the Hypothermia for Encephalopathy in Low and middle-income countries (HELIX) trial. The study was conducted in Indian hospitals, where there are around 0.5-1.0 million cases of birth asphyxia per year. Blood was taken within six hours after birth, and the infants were followed until 18 months of age to identify those who developed neurodisabilities. Two infants with blood culture positive sepsis were excluded, and the data from remaining 45 were analyzed.

Results revealed that a total of 855 genes were significantly differentially expressed between the good and adverse outcome groups, of which Regulator of G-protein Signaling 1 (RGS1) and Structural Maintenance of Chromosomes Protein 4 (SMC4) were the most significant. Biological pathway analysis adjusted for gender, treatment (cooling therapy versus usual care), and estimated blood leukocyte proportions revealed over-representation of genes from pathways related to melatonin and polo-like kinase in babies with adverse outcome.

Senior author Dr. Sudhin Thayyil, professor of perinatal neuroscience at Imperial College London, said, "The results from these blood tests will allow us to gain more insight into disease mechanisms that are responsible for brain injury and allow us to develop new therapeutic interventions or improve those which are already available."

The study was published in the August 4, 2020, online edition of the journal Scientific Reports.


Related Links:

Imperial College London

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The new ADLM guidance will help healthcare professionals navigate respiratory virus testing in a post-COVID world (Photo courtesy of 123RF)

New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections

Respiratory tract infections, predominantly caused by viral pathogens, are a common reason for healthcare visits. Accurate and swift diagnosis of these infections is essential for optimal patient management.... Read more

Molecular Diagnostics

view channel
Image: The new tests seek to detect mutant DNA in blood samples, indicating the presence of cancer cells (Photo courtesy of Christian Stolte/Weill Cornell)

Advanced Liquid Biopsy Technology Detects Cancer Earlier Than Conventional Methods

Liquid biopsy technology has yet to fully deliver on its significant potential. Traditional methods have focused on a narrow range of cancer-associated mutations that are often present in such low quantities... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Industry

view channel
Image: For 46 years, Roche and Hitachi have collaborated to deliver innovative diagnostic solutions (Photo courtesy of Roche)

Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing

Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.